IBI-327

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIBI-327

Drug Alias NameIBI-327

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor receptor superfamily member 4 agonistsT lymphocytes stimulants +[4]

TargetsTumor necrosis factor receptor superfamily member 4Programmed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInnovent Biologics (Usa), Inc

China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics (Usa), Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A